Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in attenuating coronavirus disease 2019 (Covid-19) when administered in real-world conditions.

Matéria Original

Anterior

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Próxima

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2